Breaking News, Collaborations & Alliances

Biomunex, Onward Ink Strategic Antibody Development Pact

Exclusive worldwide license and development agreement will leverage Biomunex' next gen bi- and multi-specific antibody platform in hematological malignancies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biomunex Pharmaceuticals, a biopharma company developing immunotherapy through bi- and multi-specific antibodies, and Onward Therapeutics SA, a development stage oncology company, have signed a strategic exclusive worldwide license and development agreement for a bispecific antibody program leveraging Biomunex’s next gen bi- and multi-specific antibody platform BiXAb.   Biomunex will receive an upfront payment for the license and may  receive clinical, regulatory and commercial milestone...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters